International Trade and the Global Pipeline of New GM Crops by STEIN Alexander Jivraj & RODRIGUEZ CEREZO Emilio
Stein and Rodríguez-Cerezo: supplementary notes, p. S1
Supplementary online notes 
International trade and the global pipeline of new GM crops 
November 2009 
Alexander J. Stein and Emilio Rodríguez-Cerezo  
European Commission1, Joint Research Centre (JRC),  
Institute for Prospective Technological Studies (IPTS),  
C/ Inca Garcilaso 3, 41092 Sevilla, Spain,  
contact ajstein.de and emilio.rodriguez-cerezo ec.europa.eu
Table of contents
1 Background ........................................................................................................................ 1
2 Approach............................................................................................................................ 2
2.1 Delimitation and definition of "low-level presence" .......................................................... 2
2.2 Delimitation and categorization of the pipeline of GM crops............................................ 3
2.3 Data collection ................................................................................................................ 4
3 Results, discussion and conclusions .................................................................................. 5
References................................................................................................................................. 6
Appendix .................................................................................................................................... 8
List of participants .................................................................................................................. 8
1 Background  
It is well acknowledged that national differences in the regulation of the cultivation, commercializa-
tion and use of genetically modified (GM) crops cause problems in international commodity trade, 
for instance because tolerance levels for material from approved GM crops in non-GM products 
are not harmonized (Ramessar et al. 2008). However, over the last 1-2 years also the problem of 
"asynchronous approval" of new GM crops by trading partners is rapidly gaining political relevance 
and triggering related research activities. In countries with a policy of "zero-tolerance" to even the 
smallest traces – so-called "low-level presence" – of nationally yet-unapproved GM crops, the re-
jection of shipments of agricultural commodities has caused high economic losses, threatening to 
disrupt entire supply chains (Fischer Boel 2009, Reuters 2009, Stein & Rodríguez-Cerezo 2009a, 
EC 2009, Dorey 2009, Aramyan et al. 2009, Konduru et al. 2009, Magnier et al. 2009, Krueger & Le 
Buanec 2008, Backus et al. 2008, Brookes 2008, USDA 2008, USDA 2007, EC 2007, Mitchell 2007, 
Wang & Johnston 2007, Vermij 2006).  
                                               
1 Disclaimer: The views expressed are purely those of the authors and may not in any circumstances 
be regarded as stating an official position of the European Commission.  
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Although earlier isolated incidents with traces of unapproved GM material had happened, they 
were either due to the detection of escaped research events that had not been approved for com-
mercial use anywhere in the world, or they affected crops of less relevance for the importing coun-
try. However, when a new herbicide-tolerant soybean (MON89788, known as "Roundup Ready 2" 
soybean) was submitted in 2006 for approval to United States (US) and European Union (EU) 
authorities, the European Commission's Directorate-General for Agriculture (DG AGRI) began to 
consider the consequences for the EU if the soybean would pass the US authorization procedure 
before being cleared for import at EU level. Consequently DG AGRI initiated a study to model the 
economic impact of unapproved GM crops on EU feed imports and livestock production (EC 
2007). In this study the underlying assumption was that eventually MON89788 would be approved 
in the EU and that thereafter the problem of asynchronous approval in EU soybean imports would 
be solved. MON89788 was authorized in the EU rather quickly at the end of 2008 (EC 2008), thus 
avoiding the expected problem of LLP in soybean imports to the EU. Some NGOs had argued that 
even if LLP of MON89788 in US soybean exports would have become a reality, the impact would 
have been minor for Europe because Argentina or Brazil (countries where MON89788 had not 
even been submitted for authorization) could have compensated any shortfall in the EU import of 
soybeans from the USA (FoE 2009).  
The approval of MON89788 was for some the end of the main problem for the EU concerning 
trade impacts of asynchronous approval. However, in our view, not looking further was neglectful 
because the research and development (R&D) pipeline of new GM crops could still contain clues 
to new problems related to LLP in international trade. Therefore we set out to analyze this issue 
(from a EU perspective) by formulating as working hypothesis: "The incidents of LLP so far were 
singular cases and after the approval of MON89788 soybeans by the European Commission there 
will be a period of respite without new threats to the EU's food and feed supply." In the following 
section we describe our approach to address this hypothesis.  
2 Approach  
2.1 Delimitation and definition of "low-level presence"  
Traces of nationally unapproved GM material in a country's crop supply can have three reasons:  
 There can be asynchronous approval (AA), i.e. at least one cultivating country has authorized 
a particular GM crop for commercial use while other (importing) countries have not yet 
approved this GM crop (or in these latter countries the authorization has expired already).  
 There can be isolated foreign approval (IFA), i.e. a cultivating country has authorized a 
particular GM crop for commercial use, but its developer does not seek approval in (potential or 
unattractive) importing countries.  
 There can be traces of research events, i.e. a country has authorized the cultivation of a 
GM crop in field trials only, but due to accidental admixture traces end up in the commercial 
crop supply and in crop exports.  
There is an obvious difference between traces of nationally unapproved GM material due to AA 
and IFA or due to the accidental presence of research events: in the former two cases the source 
of the traces is a GM crop that – somewhere – presumably has passed some kind of safety evalu-
ation and has been authorized for commercial use. In contrast, traces of research events neces-
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sarily come from crops that are not authorized for commercial use anywhere. Therefore in our 
analysis we did not include the accidental presence of research events in the definition of LLP.  
Another question is what level of nationally unapproved GM material constitutes a "low" level that, 
depending on the country, may be tolerated in crop shipments or not. In the USA, for instance, GM 
crops as such are not regulated; it is rather their use (e.g. as food or as pesticide) that may require 
their approval. Hence, if traces of a GM crop are detected that has not been submitted to the 
regulatory agencies, the latter determine case-by-case whether the GM crop could pose a risk and 
take proportionate measures (USDA 2007). In Switzerland traces of unapproved GM material of 
up to 0.5 percent are tolerated in food if the respective GM crop is already authorized in another 
country where comparable procedures are followed or if a danger to human health can be ex-
cluded after an ad-hoc science-based evaluation (CH 2008). In the EU there are no tolerance 
thresholds for the presence of unapproved GM events, and in practice LLP of unapproved material 
is associated to the detection level of laboratory tests. Recently the introduction of a technical 
solution for the allowance of measurement errors has been suggested by the EU Commissioner 
for Agriculture to instill confidence into the detection methods and to avoid false positives (Fischer 
Boel 2009). For our study any traces of unapproved GM material above the detection level are 
considered to represent LLP.  
2.2 Delimitation and categorization of the pipeline of GM crops  
The underlying interest of our analysis of the global pipeline of GM crops was to determine if the 
approval of the MON89788 event in the EU had solved the threat of LLP for the foreseeable future 
or how likely it is that in third countries, more new (and commercially relevant) GM crops come 
under actual cultivation soon and, therefore, pose now threats of LLP that require the attention of 
policy makers and that could affect the global agri-food supply chains. Hence the time horizon for 
our analysis was the short to medium term that was both relevant for policy making and for which 
the commercialization of a new GM crop could be confirmed with relative certainty by its developer 
(because the crop was already submitted for regulatory approval or the event had already been 
selected and final product development was already at an advanced stage and the submission of 
the event for approval was already planned). Taking the short term to be 2-3 years and the me-
dium term to be 4-7 years, we were only interested in new GM crops that could potentially reach 
the market by 2015.  
To structure the pipeline of GM crops we differentiated between six categories according to the 
crops' proximity to market (also see figure below):  
 Commercial GM crops: in at least one country worldwide the underlying GM events are 
authorized and the corresponding crops are currently marketed; crops in this category can 
cause LLP due to AA or IFA (namely if the approval of the events is delayed in some countries 
or if they are not submitted for approval in all relevant countries).  
 Commercial pipeline: in at least one country worldwide the GM events are authorized but no 
crops are marketed yet (commercialization only depends on the decision by the developer). 
 Regulatory pipeline: in at least one country worldwide the GM events are already submitted 
by their developers for authorization for commercial use (but the approval process is still 
ongoing).  
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 Advanced R&D: the GM events are not yet in the regulatory process but their developers plan 
their actual commercialization and the events are at late stages of their development (e.g. 
large-scale multi-location field trials, generation of data for the authorization dossier). 
 Earlier R&D: initial research on a new GM crop is being carried out, but there are no concrete 
plans for their commercialization yet, or e.g. the GM event that is finally to be used in the crops 
is not yet selected.  
 Other GM crops: the GM events are authorized in at least one country worldwide but they were 
never commercialized – or they were commercialized once but then phased out afterwards. 
Figure: The pipeline of GM crops from early R&D to commercialization  
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Notes: "'Other' GM crops" comprise crops that are authorized in at least one country worldwide but – for one 
reason or another – were not commercialized by their developers or are not commercialized any more.  
In view of our purpose and our time horizon, we did not focus on GM crops that are not commer-
cialized (the "other GM crops") and neither on GM crops that are still far from commercialization 
(those in an "earlier R&D" phase). Our analysis only covers GM crops in the first four categories. 
Finally, within these categories we only considered feed and food crops, i.e. we disregarded 
crops that were not (to be) authorized for the use of feed and food, like GM flowers or GM trees. 
We did not address any potential issues relating to GM animals, either.  
2.3 Data collection  
To collect data and agree on the global pipeline of GM crops that may be commercialized in the 
short to medium term, in November 2008 the Institute for Prospective Technological Studies 
(IPTS) of the European Commission's Joint Research Centre (JRC) organized an international 
two-day workshop on "The global commercial pipeline of new GM crops".  
Next to members of the European Commission and of relevant EU authorities the workshop panel 
was sampled to include representatives of:  
 the national regulatory authorities of all major countries  
where GM crops are developed or cultivated,  
 the key private companies involved in the development of GM crops,  
 the national public research systems of countries  
where GM crops are developed in the public sector,  
 international public research institutes involved in R&D of GM crops,  
 and the agri-food supply chain.
A list of the workshop participants is given in the Appendix on p. 8. Representatives from the Chi-
nese and South African regulatory agencies were invited to the workshop but did not attend in the 
end. However, public scientists from both countries attended the workshop and covered the na-
tional aspects to some extent. From the private companies only the representative from Pioneer 
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could not attend – but sent his presentation with Pioneer's pipeline of new GM crops. In any case, 
agricultural biotechnology companies as such were represented two of their industry associations 
(the Biotechnology Industry Organization and the European Association for Bioindustries).  
All experts were given time to present an overview of the current GM crops and the pipeline of 
new GM crops that falls within their expertise (jurisdiction, company, region, etc.). At the end of the 
workshop the issue of LLP was discussed in the light of this pipeline and a first structure of the 
pipeline was presented. Subsequently this information was then complemented by us in addi-
tional desk research before the overall pipeline was sent around to the experts for verification
and additional comments (Stein & Rodríguez-Cerezo 2009b). The reviewed data that emerged from 
this process is summarized in Excel file with the supplementary data, and based on this informa-
tion also the analysis of the main article was built – which the present document supplements.  
3 Results, discussion and conclusions 
The key results of our analysis are reported in the main article and are discussed in reaction to the 
Correspondence of Graff et al. (2009) on agbiotech product quality innovations and on the poten-
tial impact of the regulatory environment on R&D of GM crops (whose findings we largely confirm). 
The complete set of results is given in a technical report of the JRC where they are discussed 
more from a EU perspective, i.e. with a stronger focus on the assessment of the likelihood of fu-
ture LLP incidents with a negative impact on the EU's agri-food supply chain (Stein & Rodríguez-
Cerezo 2009a). Overall it has become clear, though, that the past LLP problems were no singular 
cases but rather harbingers of problems that can be expected to intensify when more new GM 
crops are commercialized over the next years in more countries. However, as Graff et al. (2009) 
also pointed out, strict regulations in politically powerful or economically relevant countries may 
have a detrimental impact on the development of potentially welfare-enhancing crops. If develop-
ing countries even have to fear the loss of markets for economically important export crops be-
cause of possible but unavoidable traces of unrelated GM crops, these countries may become still 
more hesitant to adopt GM crops for domestic use (that could potentially enhance productivity and 
farmer's welfare), especially if the potential beneficiaries of these crops are less powerful, less vo-
cal or more dispersed than those capitalizing on the cultivation of export crops (also see Cohen & 
Paarlberg 2002, Anderson et al. 2004, Paarlberg 2006, Gruère et al. 2009, TheParliament 2009). 
And, although our analysis has shown that most transgenic events that are currently close to 
commercialization still do not offer substantially different traits and are not introduced in new crops 
(it is mostly maize, cotton, soybeans and canola that are insect-resistant and herbicide-tolerant), 
some examples of second generation GM crops are in the pipeline.  
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